NMN
Bulk NMN powder for NAD+ precursor and healthy-aging formulation development
NMN Powder (β-Nicotinamide Mononucleotide) (CAS 1094-61-7), specification ≥99.5%. Enzymatically produced beta-NMN powder for capsule, tablet and powder formulation evaluation. Batch COA and evaluation samples are available. MOQ: 1 kg. NAD+ ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Bulk NMN powder for NAD+ precursor and healthy-aging formulation development |
| Application Scenarios | capsule and tablet formulation · NAD+ pathway research · water-soluble powder development |
| CAS Number | 1094-61-7 |
| Purity | ≥99.5% |
| Molecular Formula | C₁₁H₁₅N₂O₈P |
| Molecular Weight | 334.22 g/mol |
| Appearance | White to off-white crystalline powder |
| Solubility | Freely soluble in water |
| Storage | Sealed packaging, stored at cool, dry and away from light |
| Shelf Life | 24 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
PathGene manufactures bulk beta-NMN powder (CAS 1094-61-7) in China using an immobilized-enzyme biocatalytic process. The listed powder specification is ≥99.5% purity, with a 1 kg minimum order and 1 kg, 5 kg or 25 kg packaging. Standard lead time is 3–5 business days, subject to order confirmation. Qualified B2B buyers can request free evaluation samples, the corresponding batch COA and available third-party reports before a bulk order. Compare the same beta-NMN identity, analytical method and assay basis across supplier quotations. β-Nicotinamide mononucleotide (NMN, CAS 1094-61-7, C11H15N2O8P, MW 334.22 g/mol) is a naturally occurring nucleotide formed from nicotinamide, ribose, and a phosphate group. It occurs in trace amounts in foods such as broccoli, edamame, cabbage, and cucumber, and serves as a direct biosynthetic precursor of NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism and redox signaling. Because natural abundance is far too low for commercial extraction, bulk NMN used in supplements, cosmetic actives, and pharmaceutical-grade materials is manufactured through enzymatic/biocatalytic conversion: engineered microbial enzymes (e.g., nicotinamide riboside kinase or nicotinamide phosphoribosyltransferase), paired with an ATP-regeneration system, convert precursor substrates into NMN, which is then purified and crystallized to achieve high-purity powder form.
Purity Tested up to 99.9%
NMN purity reaches 99.9% in batch testing and third-party testing. Request the corresponding batch COA and independent report to review the result and test method.
Immobilized Enzyme Production, No Chloride Contamination
Produced via a controlled immobilized-enzyme biocatalytic process rather than chlorinated chemical routes, minimizing chloride ion residues and other process-related impurities.
Consistent Crystalline Powder
Uniform white to off-white crystalline powder with controlled particle size, freely soluble in water for easy handling in downstream formulation.
Full Contaminant & Microbial Screening
Every batch is screened for heavy metals (Pb, Hg, Cd, As), residual solvents, and microbial limits (total plate count, yeast/mold, E. coli, Salmonella) before release.
Bulk NMN Supply: 1 kg MOQ
Order beta-NMN powder in 1 kg, 5 kg or 25 kg packs. Standard lead time is 3–5 business days, subject to order confirmation. Qualified B2B buyers can request free samples, lot-specific COA and available third-party reports; OEM/private-label support remains available.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGNMN-260522
Test date
2026-05-23
Specification
Q/PGNMN-2025
Pack size
25 kg
Storage
Sealed packaging, stored at cool, dry and away from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to off-white powder | White powder |
| Identification | HPLC main peak retention time consistent with reference product | Complies |
| Purity | ≥99.0% | 99.9% |
| Assay (calculated on dry basis) | ≥99.0% | 100.0% |
| Loss on Drying | ≤2.0% | 0.19% |
| pH | 3.0–4.0 | 3.67 |
| Ethanol Residue | ≤500 ppm | Complies |
| Lead (Pb) | ≤0.1 ppm | Complies |
| Mercury (Hg) | ≤0.1 ppm | Complies |
| Cadmium (Cd) | ≤0.2 ppm | Complies |
| Arsenic (As) | ≤0.1 ppm | Complies |
| Total Microbial Count | ≤500 CFU/g | <10 CFU/g |
| Coliforms | ≤0.92 MPN/g | <0.3 MPN/g |
| Mold and Yeast | ≤50 CFU/g | <10 CFU/g |
| Staphylococcus aureus | 0/25 g | Not detected |
| Salmonella | 0/25 g | Not detected |
| Bulk Density | — | 0.60 g/mL |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Keep NMN separate from NMNH; an NAD⁺-precursor ingredient whose water solubility does not establish liquid shelf life.
99.9%
Purity
100.0%
Assay (calculated on dry basis)
PGNMN-260522 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
NMN supplies an NAD⁺ precursor, paired with resveratrol in published research; their different aqueous behaviour requires separate incorporation design.
Show research and formulation insights +Hide details −Combination / selection rationale: NMN supplies an NAD⁺ precursor, paired with resveratrol in published research; their different aqueous behaviour requires separate incorporation design.
Published evidence / source details: A 2022 mouse study reported heart and muscle NAD⁺ approximately 1.6 and 1.7 times those with NMN alone after combined resveratrol administration.
Development insights: Compare dry-blend capsules with separate formats; assay each active, uniformity and packaged retention. Liquid prototypes require resveratrol dispersion and settling tests.
Evidence scope: Animal distribution evidence does not establish human efficacy or intake.
2022 · Bai et al. · DOI 10.1002/prp2.986 ↗This combination uses specified Rg3/Rh2 material, not an interchangeable generic ginseng extract.
Show research and formulation insights +Hide details −Combination / selection rationale: This combination uses specified Rg3/Rh2 material, not an interchangeable generic ginseng extract.
Published evidence / source details: The same mouse study examined Rg3/Rh2 with NMN and reported lung NAD⁺ approximately twice the NMN-alone level after sequential oral administration.
Development insights: Specify and assay both ginsenosides; premix low-level powders before NMN and test uniformity and disintegration. Sequential dosing does not demonstrate co-capsule compatibility.
Evidence scope: Animal evidence for specified materials, not all ginseng ingredients or human outcomes.
2022 · Bai et al. · NMN / Rg3-Rh2 distribution study ↗NMN and TMG address precursor and methyl-donor systems; this is a testable formulation concept, not a requirement to take TMG with NMN.
Show research and formulation insights +Hide details −Combination / selection rationale: NMN and TMG address precursor and methyl-donor systems; this is a testable formulation concept, not a requirement to take TMG with NMN.
Published evidence / source details: An NAD⁺ metabolism review explains nicotinamide turnover and methylation pathways, without validating this exact blend in humans.
Development insights: Compare size, bulk density and moisture for powder formats; calculate each loading and test both assays, filling uniformity, moisture uptake and packaging.
Evidence scope: Mechanistic candidate, without claims of necessity or clinical synergy.
2021 · NAD⁺ metabolism review · DOI 10.1038/s41580-020-00313-x ↗NMN and PQQ are independent ingredients for NAD⁺-precursor and mitochondrial research concepts; control loading and assays separately.
Show research and formulation insights +Hide details −Combination / selection rationale: NMN and PQQ are independent ingredients for NAD⁺-precursor and mitochondrial research concepts; control loading and assays separately.
Published evidence / source details: A 2017 study treated mouse fibroblasts with PQQ and examined SIRT1/PGC-1α and mitochondrial markers; NMN was not co-administered.
Development insights: Premix PQQ with a carrier fraction before adding NMN. Assay both actives and examine start/middle/end filling, rather than judging distribution from colour alone.
Evidence scope: Single-ingredient cell evidence; the blend requires independent stability and functional evaluation.
2017 · PQQ SIRT1/PGC-1α study · DOI 10.1021/acs.biochem.7b01185 ↗Literature-Supported Research Directions
NMN is a direct nicotinamide nucleotide intermediate in NAD⁺ biosynthesis. In preclinical models, oral NMN can be utilized for NAD⁺ synthesis in peripheral tissues, supporting research into NAD⁺-dependent enzymes, DNA-repair signaling and mitochondrial homeostasis.
Citation: Mills et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell metabolism (2016). PMID: 28068222.View source
In a 10-week randomized, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese, NMN supplementation increased skeletal-muscle insulin sensitivity and insulin signaling. This supports further research into NAD⁺ turnover, muscle remodeling and metabolic formulation strategies.
Citation: Yoshino et al., Science 372 (2021), 1224–1229.View source
In aged-mouse studies, NMN supplementation was associated with improved age-related endothelial dysfunction and reduced measures of large-artery stiffness. These findings support continued investigation of NAD⁺-SIRT1 signaling and vascular-aging models.
Citation: de Picciotto et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. npj Aging and Mechanisms of Disease (2016). PMCID: PMC4854911.View source
NMN has been studied in amyloid-related neuronal injury and Alzheimer’s disease models, where researchers observed changes in NAD⁺/ATP, oxidative stress and cognitive-test outcomes. The evidence remains preclinical and is best presented as a neurobiology research direction.
Citation: Wang et al., Brain Research (2016), NMN in amyloid-β oligomer-induced neuronal injury and cognitive-impairment models.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Associated Patents
ZL 2022 1 0234567.X
Granted Chinese Invention Patent — core synthesis process protected by IP, ensuring supply stability and proprietary process exclusivity.
+ PathGene holds 12 core invention patents in total
Biocatalyst Fermentation
An engineered microbial strain expressing the target enzyme (e.g., nicotinamide riboside kinase or nicotinamide phosphoribosyltransferase) is cultivated by fermentation to produce the biocatalyst in a controlled bioreactor.
Enzyme Extraction & Immobilization
The enzyme is extracted, purified, and immobilized onto a solid carrier, enabling reuse across reaction cycles and reducing ionic and chemical residues compared with solution-phase chemical synthesis.
Substrate & Cofactor Preparation
Precursor substrate (nicotinamide riboside, or nicotinamide with 5-phosphoribosyl-1-pyrophosphate) is prepared alongside an ATP-regeneration system to sustain the phosphorylation/condensation reaction at scale.
Enzymatic Bioconversion
Under controlled temperature and pH, the immobilized enzyme catalyzes conversion of the substrate into NMN within a stirred-tank or packed-bed bioreactor, monitored for conversion yield in real time.
Biomass & Enzyme Carrier Removal
Reaction broth is clarified by filtration/centrifugation to separate the immobilized enzyme carrier and residual biomass from the product stream.
Purification & Ion Removal
The crude NMN solution undergoes chromatographic and/or ion-exchange purification to remove salts, chloride ions, and byproducts, concentrating the target compound.
Crystallization, Drying & Milling
Controlled crystallization yields high-purity NMN crystals, which are then vacuum-dried and milled to a consistent particle size for the finished powder.
Quality Control & Packaging
Finished batches are tested for assay (HPLC), heavy metals, and microbial limits, then packed under nitrogen-flushed, moisture-protected conditions with a batch COA.
NMN purity is tested by HPLC. Batch testing and third-party testing can reach 99.9%; consult the corresponding report for the lot and method. Product acceptance specifications and measured batch results are shown separately.
NMN is freely soluble in water. It can be evaluated in capsules, tablets, sachets, ready-to-mix powders and cosmetic aqueous systems. For liquid or topical prototypes, test assay retention and stability at the intended concentration, pH, processing temperature and packaging conditions. A powder specification does not demonstrate sterility, injectable suitability or superior absorption for a delivery format.
Yes. PathGene manufactures beta-NMN powder, CAS 1094-61-7, using an immobilized-enzyme process, with a purity specification of ≥99.5%. Material-specific process information, batch COAs and corresponding third-party reports support manufacturer qualification.
Store beta-NMN powder sealed in a cool, dry place away from light. Its listed shelf life is 24 months; the supplied lot label and documents identify the applicable expiry date. Minimize moisture and air exposure after opening. Finished formulations require their own stability studies.
Specify beta-NMN, CAS 1094-61-7, the agreed assay basis and limits, and the delivery lot. PathGene lists this powder at ≥99.5% purity; a lot result or third-party report applies to the tested material. Confirm the quantity, packaging and destination with the quotation, then match the supplied lot to its COA.
Each batch is tested by HPLC against a reference standard, with a Certificate of Analysis (COA) issued per batch. Buyers are welcome to request the COA for the specific lot before purchase, and third-party verification is supported.
Our NMN is produced via an immobilized-enzyme biocatalytic process, avoiding chlorinated chemical routes and their associated chloride ion residues. This enzymatic approach supports high purity and consistent batch-to-batch quality.
NMN powder is readily soluble in water and can be evaluated in capsules, tablets, sachets, ready-to-mix powders and cosmetic aqueous systems. Test stability at the intended concentration, pH, processing temperature and packaging conditions. Establish inclusion levels through formulation testing and destination-market requirements.
Yes, samples are available for qualified B2B buyers to evaluate purity, appearance, and solubility ahead of a bulk order. Please contact our sales team to arrange sample shipment and documentation.
Yes, buyers are free to submit samples to third-party laboratories of their choice for independent verification of purity, heavy metals, and microbial limits. We are happy to cooperate with recognized testing bodies.
Yes, we support OEM/private-label collaboration, including formulation guidance for capsules, sublingual tablets, sachets, and topical serums, in addition to supplying bulk raw material.
The raw-material MOQ for NMN powder is 1 kg, with pack options of 1 kg, 5 kg, 25 kg. Typical lead time is 3–5 business days, with dispatch confirmed for the order.
Yes. NMN purity can reach 99.9% in third-party testing. Request the corresponding report and batch COA when qualifying the ingredient; the results relate to the tested material.
The typical lead time for NMN raw material is 3–5 business days, with dispatch confirmed for the order. Qualified B2B buyers can request free evaluation samples for purity, solubility and formulation-compatibility testing. Shipping arrangements are confirmed separately.
Compare the same beta-NMN identity and CAS 1094-61-7 first, then the analytical method, purity versus assay basis, water, related substances and lot-matched COA. Compare pack sizes, MOQ and delivery terms on that same specification. PathGene supplies ≥99.5% powder with a 1 kg MOQ, 1/5/25 kg packs and a standard 3–5 business-day lead time, subject to order confirmation. A chromatographic purity percentage alone is not a complete supplier qualification.
No. A release COA reports quality results for the tested powder lot. Capsule, tablet, powder-blend and liquid projects have different formulation, process and packaging conditions. Define a stability study for the actual product and use a suitable method to track NMN content and relevant quality attributes.
Specify beta-NMN and the selected resveratrol form, each assay basis and loading. Compare dry blending or separate formats and test both actives, uniformity, disintegration and storage retention. Published animal co-administration informs research design; it does not validate a finished capsule or establish a human dose.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Independent test record · Available by product/batch
Technical Resources
A head-to-head technical comparison of NMN and NR for nutraceutical and pharmaceutical formulators — covering bioavailability, stability, purity targets, and regulatory status.
A practical NMN buyer checklist for separating HPLC purity from assay, checking the reporting basis, reviewing related substances and matching every result to the actual commercial batch.
Read an NMN batch COA using a disclosed lot example, distinguishing product specifications, purity, dry-basis assay and shipment acceptance.
Related Products
β-Nicotinamide Adenine Dinucleotide (NAD+) Powder
Nicotinamide Riboside Chloride Powder
Nicotinamide Riboside Hydrogen Malate Powder
Reduced Nicotinamide Mononucleotide (NMNH) Powder
Interested in NMN?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
